Chop-Lump tests for vaccine trials

Biometrics

Volumn 65, Issue 3, 2009, Pages 885-893

  Follmann, Dean ^a   Fay, Michael P ^a   Proschan, Michael ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Lachenbruch's test; Permutation; Principal stratification; Rank tests; Semicontinuous data; Sensitivity analysis

Indexed keywords

BIOMETRICS; DISEASES; VACCINES;

LACHENBRUCH TEST; PERMUTATION; PLACEBO GROUPS; POWER; PRINCIPAL STRATIFICATION; RANK TEST; SEMI-CONTINUOUS; SEMICONTINUOUS DATA; T-TESTS; WILCOXON TEST;

SENSITIVITY ANALYSIS;

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MALARIA VACCINE; PLACEBO;

SENSITIVITY ANALYSIS; TESTING METHOD; VACCINE;

ANALYTIC METHOD; ARTICLE; CHOP LUMP TEST; CLINICAL TRIAL; CONTROLLED STUDY; INFECTION; METHODOLOGY; RANDOMIZATION; RANK SUM TEST; SCORING SYSTEM; SIMULATION; STATISTICAL ANALYSIS; STUDENT T TEST; VOLUNTEER;

AIDS VACCINES; BIOMETRY; CLINICAL TRIALS, PHASE III AS TOPIC; DATA INTERPRETATION, STATISTICAL; HIV INFECTIONS; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PLACEBO EFFECT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 70349248346     PISSN: 0006341X     EISSN: 15410420     Source Type: Journal    
DOI: 10.1111/j.1541-0420.2008.01131.x     Document Type: Article

References (23)

1. Angrist, J. D., Imbens, G. W., and Rubin, D. B. (1996). Identification of causal effects using instrumental variables. Journal of the American Statistical Association 91, 444 455.
2. Burke, D. S. (1992). Human HIV vaccine trials: Does antibody dependent enhancement pose a genuine risk Perspectives in Biology and Medicine 35, 511 530.
3. Chang, M. N., Guess, H. A., and Heyse, J. F. (1994). Reduction in burden of illness: A new efficacy measure for prevention trials. Statistics in Medicine 13, 1807 1814.
4. Frangakis, C. E. and Rubin, D. B. (2002). Principal stratification in causal inference. Biometrics 58, 21 29.
5. Flynn, N. M., Forthal, D. N., Harro, C. D., Judson, F. N., Mayer, K. H., Para, M. F., Gilbert, P. B., Hudgens, M. G., Metch, B. J., Self, S. G., Berman, P. W., Francis, D. P., Gurwith, M., Heyward, W. L., Peterson, M. L., Popovic, V., and Sinangil, F. M. (2005). Placebo-controlled phase 3 of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. Journal of Infectious Diseases 191, 654 665.
6. Gilbert, P. B., Bosch, R. J., and Hudgens, M. G. (2003). Sensitivity analysis for the assessment of causal vaccine effects on viral load in HIV vaccine trials. Biometrics 59, 531 541.
7. Gilbert, P. B., Ackers, M. L., Berman, P. W., Francis, D. P., Popovic, V., Hu, D. J., Heyward, W. L., Sinangil, F., Shepherd, B. E., and Gurwith, M. (2005). HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine. Journal of Infectious Diseases 192, 974 983.
8. Girard, M. P., Reed, Z. H., Friede, M., and Kieny, M. P. (2007). A review of human vaccine research and development: Malaria. Vaccine 25, 1567 1580.
9. Halloran, M. E., Struchiner, C. J., and Longini, I. (1997). Study designs for evaluating different efficacy and effectiveness aspects of vaccines. American Journal of Epidemiology 146, 789 803.
10. Hudgens, M. G., Hoering, A., and Self, S. G. (2003). On the analysis of viral load endpoints in HIV vaccine trials. Statistics in Medicine 22, 2281 2298.
11. Jemiai, Y. (2005). Semiparametric methods for inferring treatment effects on outcomes defined only if a post-randomization event occurs. Ph.D. Thesis, Harvard Department of Biostatistics, Cambridge, Massachusetts.
12. Lachenbruch, P. A. (2001). Comparisons of two-part models with competitors. Statistics in Medicine 20, 1215 1234.
13. Lehmann, E. (1975). Nonparametrics: Statistical Methods Based on Ranks. Oakland, California : Holden Day.
14. Lyles, R. H., Munoz, A., Yamashita, T. E., Bazmi, H., and Detels, R. (2000). Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. Journal of Infectious Diseases 181, 872 880.
15. Mehrotra, D. V., Li, X. M., and Gilbert, P. B. (2006). A comparison of eight methods for the dual-endpoint evaluation of efficacy in a proof-of-concept HIV vaccine trial. Biometrics 62, 893 900.
16. Robins, J. M. (1995). An analytic method for randomized trials with informative censoring: Part I. Lifetime Data Analysis 1, 241 254.
17. Scharfstein, D. O., Rotnitzky, A., and Robins, J. M. (1999). Adjusting for nonignorable drop-out using semiparametric nonresponse models. Journal of the American Statistical Association 94, 1096 1120.
18. Shepherd, B. E., Gilbert, P. B., Jemiai, Y., and Rotnitzky, A. (2006). Sensitivity analyses comparing outcomes only existing in a subset selected post-randomization, conditional on covariates, with application to HIV vaccine trials. Biometrics 62, 332 342.
19. Shepherd, B. E., Redman, M. W., and Ankerst, D. P. (2008). Does finasteride affect the severity of prostate cancer A causal sensitivity analysis. Journal of the American Statistical Association, to appear.
20. Smith, T., Schellenberg, J. A., and Hayes, R. (1994). Attributable fraction estimates and case definitions for malaria in endemic areas. Statistics in Medicine 13, 2345 2358. (Pubitemid 24354857)
21. Steinbrook, R. (2007). One step forward, two steps back, will there ever be an AIDS vaccine New England Journal of Medicine 356, 2653 2655.
22. Struchiner, C. J. and Halloran, M. E. (2007). Randomization and baseline transmission in vaccine field trials. Epidemiology and Infection 135, 181 194.
23. Tu, W. and Zhou, X.-H. (1999). A Wald test comparing medical costs based on log-normal distributions with zero valued costs. Statistics in Medicine 18, 2749 2761.